2269: WuXi Biologics (Cayman) Inc. - Summary | Jitta

WuXi Biologics (Cayman) Inc.

HKG:2269

Price
HK$46.40
Loss Chance
44.0%
6.23JITTA SCORE
52.72%Over Jitta Line
Jitta Ranking
29 / 182
311 / 2,332
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (74)
Recent Business Performance (66)
Financial Strength (75)
Return to Shareholders (19)
Competitive Advantage (69)
Jitta Signs
Revenue and EarningConsistent High Growth in the past 5 years
Recent Business PerformanceEarning Growth Last Year
Debt LevelLow Long Term Debt
SG&A to SalesDecreasing
CapExVery High
Cash Conversion CycleMore than 120 days
Key Stats
Jitta Score
Jitta Line
6.23
52.72%
3.67
584.48%
Life Sciences Tools and Services
5.40
31.75%
2.45
100.00%
3.69
13.31%
COMPANY DESCRIPTION
WuXi Biologics (Cayman) Inc. provides end-to-end solutions and services for biologics discovery, development and manufacturing in the People’s Republic of China, North America, Europe, and internationally. The company also engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, and biologics clinical and manufacturing services; production and sale of medicals; vaccine CDMO and related business; and material supplier activities. WuXi Biologics (Cayman) Inc. has strategic partnership with ImmuneOncia Therapeutics, Legochem Biosciences Inc, Worg Pharma, OncoC4, and Exelixis Inc. The company was incorporated in 2014 and is headquartered in Wuxi, China.